Expand ATNM Menu
ATNM MENU

ATNM Stock Summary and Trading Ideas (Actinium Pharmaceuticals (Delaware) | AMEX:ATNM)

Charts for Today's Stock Price and Implied Volatility in Actinium Pharmaceuticals (Delaware)

24-Apr-2024

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for ATNM by Theoretical Edge and Win Rates

Sentiment

News

No headlines found.

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

PRNewswire (Thu, 18-Apr 8:00 AM ET)

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

PRNewswire (Mon, 1-Apr 8:00 AM ET)

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

PRNewswire (Tue, 26-Mar 7:18 AM ET)

Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge

InvestorBrandMedia (Thu, 21-Mar 7:20 PM ET)

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

PRNewswire (Mon, 11-Mar 7:30 AM ET)

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

PRNewswire (Mon, 26-Feb 7:30 AM ET)

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

PRNewswire (Fri, 23-Feb 7:30 AM ET)

Trading Statistics

Key Ratios

Actinium Pharmaceuticals (Delaware) (ATNM) Frequently Asked Questions

What does Actinium Pharmaceuticals (Delaware) do?

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

What symbol and exchange does Actinium Pharmaceuticals (Delaware) stock trade?

Actinium Pharmaceuticals (Delaware) trades on the AMEX stock market under the symbol ATNM.

What is Actinium Pharmaceuticals (Delaware) stock price doing today?

As of April 24, 2024, ATNM stock price climbed to $7.06 with 151,055 million shares trading.

What is Actinium Pharmaceuticals (Delaware)'s Beta?

ATNM has a beta of 1.17, meaning it tends to be more sensitive to market movements. ATNM has a correlation of 0.04 to the broad based SPY ETF.

How much is Actinium Pharmaceuticals (Delaware) worth?

ATNM has a market cap of $193.54 million. This is considered a Micro Cap stock.

What is the highest and lowest price Actinium Pharmaceuticals (Delaware) traded in the last 3 year period?

In the last 3 years, ATNM stock traded as high as $15.12 and as low as $4.00.

What are the top ETFs holding Actinium Pharmaceuticals (Delaware)?

The top ETF exchange traded funds that ATNM belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

Is Actinium Pharmaceuticals (Delaware) (ATNM) a good investment?

ATNM has underperformed the market in the last year with a price return of -24.1% while the SPY ETF gained +24.2%. However, in the short term, ATNM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +37.4% vs +4.6% return in SPY. But in the last 2 weeks, ATNM shares have been beat by the market, returning -21.4% compared to an SPY return of -2.7%.

What is the support and resistance for Actinium Pharmaceuticals (Delaware) (ATNM) stock price?

ATNM support price is $6.58 and resistance is $7.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATNM stock will trade within this expected range on the day.